Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2011

View Archived Issues

Phase II/III data on antidiabetic efficacy of insulin degludec and insulin degludec/insulin aspart

Gilead Sciences announces CHMP's opinion on Eviplera

Positive CHMP opinion on new indications for Xarelto

European approval recommended for Levemir as add-on to Victoza

Scientists present phase II data on TAS-102 in CRC and potential predictors of efficacy

New data reported from proof-of-principle phase I trial of virosome-based HIV vaccine

Partial hold placed on Immunomedics' trial of yttrium (Y90) clivatuzumab tetraxetan

Faslodex approved in Japan

Indian company prepares new AAV vector-based therapies for cancer

Scientists present 5-year phase II data on odanacatib in postmenopausal women with low BMD

Novel compounds for dermatological disorders presented

Study links gamma-enolase levels to febrile seizures in children

Pegasys approved for new indication in Japan

Asahi Kasei Pharma clear to market osteoporosis therapy in Japan

Synthesis and activity of novel IRAK-4 inhibitors described

Kombiglyze recommended for approval in E.U.

Novel compositions for regulating HER4 reported

U.S. hospital presents new HCV-targeted microRNA products

Additional FDA orphan drug designation for resminostat

Japanese authorities extend indication of Venogloblulin

Piramal Life Sciences patents novel TGF-beta inhibitors for cancer

Ono Pharmaceutical obtains approval in Japan for intravenous Proemend

FDA approves new indication for Soliris

Mucosta approved in Japan for dry eye syndrome

CHMP recommends approval of Alimta for new indication

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Latus Bio series A financing supports early-stage programs
BioWorld Science
Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the...